Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369689 | 0.92 | MRGPRX4 (0.60) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL12523729 | 0.92 | MRGPRX4 (0.57) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL5691491 | 0.92 | MAOB (0.62) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL12525375 | 0.92 | MRGPRX4 (0.57) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL7369690 | 0.92 | MRGPRX4 (0.60) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL5249481 | 0.91 | HRH3 (0.60) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL27853765 | 0.90 | MRGPRX4 (0.58) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL20930997 | 0.89 | MAOB (0.62) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL9441348 | 0.88 | MRGPRX4 (0.64) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30215671 | 0.88 | MRGPRX4 (0.53) | MRGPRX4LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-05-10 | — | — | US | disclosed |
| EP-2598482-B1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-04-04 | — | — | EP | disclosed |
| US-9908859-B2 | Lysine demethylase inhibitors for myeloproliferative disorders | ORYZON GENOMICS, S.A. (ES) | 2018-03-06 | — | — | US | disclosed |
| CN-107417549-A | As LSD1 inhibitor（It is miscellaneous）Aryl cyclopropyl amines | 奥莱松基因组股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-9708309-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2017-07-18 | — | — | US | disclosed |
| EP-3133059-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2017-02-22 | — | — | EP | disclosed |
| WO-2017013061-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2017-01-26 | — | — | WO | disclosed |
| EP-2560947-B1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2016-10-12 | — | — | EP | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| EP-2067775-A1 | Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | MRGPRX4 2536/4885LMNA 3206/4885CYP1A2 78/4885 |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | MRGPRX4 2536/4885LMNA 3206/4885CYP1A2 78/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | MRGPRX4 3766/4885LMNA 584/4885CYP1A2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.